Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder

References

• Aarsland D, Andersen K, Larsen J, et al. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology. 2001;56(6):730–736.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36–42.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Brønnick K, Larsen J, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest Study. Neurology. 2009;72(13):1121–1126.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24(15):2175–2186.
   PubMed Web of Science ®Google Scholar
• Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature. 2016;539(7628):207–216.
   PubMed Web of Science ®Google Scholar
• Adamczyk A, Kaźmierczak A, Strosznajder JB. α-synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide. Neurochem Int. 2006;49(4):407–412.
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Arabi A. Vitamins and bone health: beyond calcium and vitamin D. Nutr Rev. 2011;69(10):584–598.
   PubMed Web of Science ®Google Scholar
• Allcock LM, Kenny RA, Mosimann UP, et al. Orthostatic hypotension in Parkinson’s disease: association with cognitive decline? Int J Geriatr Psychiatry. 2006;21(8):778–783.
   PubMed Web of Science ®Google Scholar
• Allen SJ, Watson JJ, Shoemark DK, et al. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138(2):155–175.
   PubMed Web of Science ®Google Scholar
• Aloe L, Bracci-Laudiero L, Bonini S, et al. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy. 1997;52(9):883–994.
   PubMed Web of Science ®Google Scholar
• Alves G, Müller B, Herlofson K, et al. Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2009;80(8):851–857.
   PubMed Web of Science ®Google Scholar
• Amboni M, Cozzolino A, Longo K, et al. Freezing of gait and executive functions in patients with Parkinson’s disease. Mov Disord. 2008;23(3):395–400.
   PubMed Web of Science ®Google Scholar
• Ansari K, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chronic Dis. 1975; 28(9):493–497.
   PubMedGoogle Scholar
• Arias P, Cudeiro J. Effect of rhythmic auditory stimulation on gait in Parkinsonian patients with and without freezing of gait. PLoS One. 2010;5(3):e9675.
   PubMed Web of Science ®Google Scholar
• Arima K, Ueda K, Sunohara N, et al. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson’s disease and in dementia with Lewy bodies. Brain Res. 1998;808(1):93–100.
   PubMed Web of Science ®Google Scholar
• Armentero MT, Pinna A, Ferré S, et al. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson’s disease. Pharmacol Ther. 2011;132(3):280–299.
   PubMed Web of Science ®Google Scholar
• Ashkan K, Wallace B, Bell B, et al. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 1993–2003: where are we 10 years on? Br J Neurosurg. 2004;8(1):19–34.
   Web of Science ®Google Scholar
• Ashok P, Radhakrishnan K, Sridharan R, et al. Epidemiology of Parkinson’s disease in Benghazi, north-east Libya. Clin Neurol Neurosurg. 1986;88(2):109–113.
   PubMed Web of Science ®Google Scholar
• Au Yeung S, Jiang C, Cheng K, et al. Evaluation of moderate alcohol use and cognitive function among men using a Mendelian randomization design in the Guangzhou biobank cohort study. Am J Epidemiol. 2012;75(10):1021–1028.
   Web of Science ®Google Scholar
• Auluck PK, Chan HE, Trojanowski JQ, et al. Chaperone suppression of α-Synuclein toxicity in a drosophila model for Parkinson’s disease. Science. 2002;295(5556):865–868.
   PubMed Web of Science ®Google Scholar
• Azulay JP, Mesure S, Blin O. Influence of visual cues on gait in Parkinson’s disease: contribution to attention or sensory dependence? J Neurol Sci. 2006;248(1):192–195.
   PubMed Web of Science ®Google Scholar
• Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol. 1998;152(4):879.
   PubMed Web of Science ®Google Scholar
• Bala V, Debnath A, Shill A, et al. Anti-inflammatory, diuretic and antibacterial activities of aerial parts of Mucuna pruriens Linn. Int J Pharmacol. 2011;7(4):498–503.
   Web of Science ®Google Scholar
• Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000;55(9):1358–1363.
   PubMed Web of Science ®Google Scholar
• Ballard C, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology. 2002;59(11):1714–1720.
   PubMed Web of Science ®Google Scholar
• Baluchnejadmojarad T, Roghani M, Khastehkhodaie Z. Chronic treatment of silymarin improves hyperalgesia and motor nerve conduction velocity in diabetic neuropathic rat. Phytother Res. 2010;24(8):1120–1125.
   PubMed Web of Science ®Google Scholar
• Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study). Mov Disord. 2006;21(6):800–808.
   PubMed Web of Science ®Google Scholar
• Barker RA, Barrett J, Mason SL, et al. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet Neurol. 2013;2(1):84–91.
   Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–580.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Weinberg MS, Samulski RJ. Parkinson’s disease gene therapy: success by design meets failure by efficacy. Mol Ther. 2014;22(3):487–497.
   PubMed Web of Science ®Google Scholar
• Beal MF, Matthews RT, Tieleman A, et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783(1):109–114.
   PubMed Web of Science ®Google Scholar
• Bedford L, Hay D, Devoy A, et al. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci. 2008;28(33):8189–8198.
   PubMed Web of Science ®Google Scholar
• Bellingham SA, Guo BB, Coleman BM, et al. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol. 2012;3:124.
   PubMed Web of Science ®Google Scholar
• Benabid AL, Chabardes S, Mitrofanis J, et al. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol. 2009;8(1):67–81.
   PubMed Web of Science ®Google Scholar
• Benvenuti F, Stanhope S, Thomas S, et al. Flexibility of anticipatory postural adjustments revealed by self-paced and reaction-time arm movements. Brain Res. 1997;761(1):59–70.
   PubMed Web of Science ®Google Scholar
• Berardelli A, Rothwell J, Thompson P, et al. Pathophysiology of bradykinesia in Parkinson’s disease. Brain. 2001;124(11):2131–2146.
   PubMed Web of Science ®Google Scholar
• Bessler H, Djaldetti R, Salman H, et al. IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson’s disease. Biomed Pharmacother. 1999;53(3):141–145.
   PubMed Web of Science ®Google Scholar
• Betarbet R, Canet-Aviles RM, Sherer TB, et al. Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis. 2006;22(2):404–420.
   PubMed Web of Science ®Google Scholar
• Beuter A, Labrie C, Vasilakos K. Transient dynamics in motor control of patients with Parkinson’s disease. Chaos. 1991;1(3):279–286.
   PubMed Web of Science ®Google Scholar
• Björklund A, Kirik D, Rosenblad C, et al. Towards a neuroprotective gene therapy for Parkinson’s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 2000;886(1–2):82–98.
   PubMed Web of Science ®Google Scholar
• Björklund LM, Sánchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA. 2002;99(4):2344–2349.
   PubMed Web of Science ®Google Scholar
• Bloem BR, Grimbergen YA, Cramer M, et al. Prospective assessment of falls in Parkinson’s disease. J Neurol. 2001;248(11):950–958.
   PubMed Web of Science ®Google Scholar
• Blum D, Torch S, Lambeng N, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol. 2001;65(2):135–172.
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Ferman TJ. 2004. REM sleep behavior disorder in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17(3):146–157.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Archives Neurol. 2003;60(12):1745–1748.
   PubMed Web of Science ®Google Scholar
• Bonifati V, Rizzu P, Van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):256–259.
   PubMed Web of Science ®Google Scholar
• Bonnet AM, Loria Y, Saint-Hilaire M-H, et al. Does long-term aggravation of Parkinson’s disease result from nondopaminergic lesions? Neurology. 1987;37(9):1539.
   PubMed Web of Science ®Google Scholar
• Borek LL, Kohn R, Friedman JH. Phenomenology of dreams in Parkinson’s disease. Mov Disord. 2007;22(2):198–202.
   PubMed Web of Science ®Google Scholar
• Bouisset S, Do MC. Posture, dynamic stability, and voluntary movement. Neurophysiol Clin. 2008;38(6):345–362.
   PubMed Web of Science ®Google Scholar
• Bové J, Prou D, Perier C, et al. Toxin-induced models of Parkinson’s disease. NeuroRx. 2005;2(3):484–494.
   PubMedGoogle Scholar
• Bové J, Zhou C, Jackson-Lewis V, et al. Proteasome inhibition and Parkinson’s disease modeling. Ann Neurol. 2006;60(2):260–264.
   PubMed Web of Science ®Google Scholar
• Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999;52(6):1214.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
   PubMed Web of Science ®Google Scholar
• Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68(2):165.
   PubMed Web of Science ®Google Scholar
• Brown P, Oliviero A, Mazzone P, et al. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson’s disease. J Neurosci. 2001;21(3):1033–1038.
   PubMed Web of Science ®Google Scholar
• Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010;11(4):301–307.
   PubMed Web of Science ®Google Scholar
• Brunt E, Brooks D, Korczyn A, et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by L-dopa. J Neural Transm. 2002;109(4):489–501.
   Google Scholar
• Burleigh-Jacobs A, Horak FB, Nutt JG, et al. Step initiation in Parkinson’s disease: influence of levodopa and external sensory triggers. Mov Disord. 1997;12(2):206–215.
   PubMed Web of Science ®Google Scholar
• Caballol N, Martí MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord. 2007;22(S17):S358–S366.
   PubMed Web of Science ®Google Scholar
• Canet-Avilés RM, Wilson MA, Miller DW, et al. The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA. 2004;101(24):9103–9108.
   PubMed Web of Science ®Google Scholar
• Caradoc-Davies T, Weatherall M, Dixon G, et al. Is the prevalence of Parkinson’s disease in New Zealand really changing? Acta Neurol Scand. 1992;86(1):40–44.
   PubMed Web of Science ®Google Scholar
• Castano A, Herrera A, Cano J, et al. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem. 1998;70(4):1584–1592.
   PubMed Web of Science ®Google Scholar
• Castano A, Herrera A, Cano J, et al. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem. 2002;81(1):150–157.
   PubMed Web of Science ®Google Scholar
• Chartier-Harlin MC, Kachergus J, Roumier C, et al. α-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet. 2004;364(9440):1167–1169.
   PubMed Web of Science ®Google Scholar
• Chastan N, Do MC, Bonneville F, et al. Gait and balance disorders in Parkinson’s disease: impaired active braking of the fall of centre of gravity. Mov Disord. 2009;24(2):188–195.
   PubMed Web of Science ®Google Scholar
• Chastan N, Westby G, Yelnik J, et al. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson’s disease. Brain. 2009;132172–184.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245.
   PubMed Web of Science ®Google Scholar
• Cheng W, Li Y, Hou X, et al. HSP60 is involved in the neuroprotective effects of naloxone. Mol Med Rep. 2014;10(4):2172–2176.
   PubMed Web of Science ®Google Scholar
• Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med. 2001;7(10):1144–1150.
   PubMed Web of Science ®Google Scholar
• Clarke C. Medical management of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;72(1):i22–i27.
   PubMed Web of Science ®Google Scholar
• Compta Y, Parkkinen L, O’sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain. 2011;134(5):1493–1505.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683.
   PubMed Web of Science ®Google Scholar
• Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4(11):1318–1320.
   PubMed Web of Science ®Google Scholar
• Cools R, Barker RA, Sahakian BJ, et al. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia. 2003;41(11):1431–1441.
   PubMed Web of Science ®Google Scholar
• Cooper JM, Wiklander P, Nordin JZ, et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord. 2014;29(12):1476–1485.
   PubMed Web of Science ®Google Scholar
• Coppes OM, Sang CN. Indications for opioid antagonists. Curr Pain Headache Rep. 2017;21(6):30.
   PubMed Web of Science ®Google Scholar
• Corrado C, Raimondo S, Chiesi A, et al. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci. 2013;14(3):5338–5366.
   PubMed Web of Science ®Google Scholar
• Cossu G, Ceravolo R, Zibetti M, et al. Levodopa and neuropathy risk in patients with Parkinson disease: effect of COMT inhibition. Parkinsonism Relat Disord. 2016;27:81–84.
   PubMed Web of Science ®Google Scholar
• Coune PG, Schneider BL, Aebischer P. Parkinson’s disease: gene therapies. Cold Spring Harb Perspect Med. 2012; 2(4):a009431.
   PubMed Web of Science ®Google Scholar
• Craparo EF, Bondì ML, Pitarresi G, et al. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther. 2011;17(6):670–677.
   PubMed Web of Science ®Google Scholar
• Crenna P, Carpinella I, Rabuffetti M, et al. Impact of subthalamic nucleus stimulation on the initiation of gait in Parkinson’s disease. Exp Brain Res. 2006;172(4):519–532.
   PubMed Web of Science ®Google Scholar
• Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292–1295.
   PubMed Web of Science ®Google Scholar
• Das KP, McMillian MK, Bing G, et al. Modulatory effects of [Met5]-enkephalin on interleukin-1 beta secretion from microglia in mixed brain cell cultures. J Neuroimmunol. 1995;62(1):9–17.
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909.
   PubMed Web of Science ®Google Scholar
• De Lau L, Koudstaal PJ, Witteman J, et al. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology. 2006;67(2):315–318.
   PubMed Web of Science ®Google Scholar
• De Rijk M, Launer L, Breteler M, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;4:S21–3.
   Google Scholar
• de Rijk MC, Breteler MM, den Breeijen JH, et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol. 1997;54(6):762–765.
   PubMedGoogle Scholar
• de Tassigny XdA, Pascual A, López-Barneo J. GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease. Front Neuroanat. 2015;9:10.
   Web of Science ®Google Scholar
• De Toro J, Herschlik L, Waldner C, et al. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol. 2015;6:203.
   Web of Science ®Google Scholar
• Defebvre LJ, Krystkowiak P, Blatt JL, et al. Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson’s disease. Mov Disord. 2002;7(1):76–83.
   Web of Science ®Google Scholar
• Dehay B, Ramirez A, Martinez-Vicente M, et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci. 2012;109(24):9611–9616.
   PubMed Web of Science ®Google Scholar
• Deng HX, Shi Y, Yang Y, et al. Identification of TMEM230 mutations in familial Parkinson’s disease. Nat Genet. 2016;48(7):733–739.
   PubMed Web of Science ®Google Scholar
• Deng R, Hua X, Li J, et al. Oxidative stress markers induced by hyperosmolarity in primary human corneal epithelial cells. PLoS One. 2015;10(5):e0126561.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355(9):896–908.
   PubMed Web of Science ®Google Scholar
• Devasagayam T, Tilak J, Boloor K, et al. Free radicals and antioxidants in human health: current status and future prospects. J Assoc Phys India. 2004;52(10):794–804.
   Google Scholar
• Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008;283(14):9089–9100.
   PubMed Web of Science ®Google Scholar
• Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850–857.
   PubMed Web of Science ®Google Scholar
• Di Filippo M, Sarchielli P, Picconi B, et al. Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci. 2008;29(8):402–412.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771–784.
   PubMed Web of Science ®Google Scholar
• Dibble LE, Nicholson DE, Shultz B, et al. Sensory cueing effects on maximal speed gait initiation in persons with Parkinson’s disease and healthy elders. Gait Posture. 2004;19(3):215–225.
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Menza M, Allen LA, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2011;24(4):206–214.
   PubMed Web of Science ®Google Scholar
• Dong W, Gu WX, Tang XW, et al. Effect of berberine combined with risperidone therapy on endocrine hormones and oxidative stress in patients with schizophrenia. JHMU. 2017;23(13):151–154.
   Google Scholar
• Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38(8):1237.
   PubMed Web of Science ®Google Scholar
• Drijgers RL, Dujardin K, Reijnders JS, et al. Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(10):656–660.
   PubMed Web of Science ®Google Scholar
• Dujardin K, Sockeel P, Delliaux M, et al. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord. 2009;24(16):2391–2397.
   PubMed Web of Science ®Google Scholar
• Dunnett SB, Björklund A, Lindvall O. Cell therapy in Parkinson’s disease - stop or go? Nat Rev Neurosci. 2001;2(5):365–369.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson’s disease. Antioxid Redox Signalt. 2003;5(3):319–335.
   PubMed Web of Science ®Google Scholar
• Ejaz AA, Kazory A, Heinig ME. 24-hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension. J Clin Hypertens (Greenwich). 2007;9(12):952–955.
   PubMedGoogle Scholar
• Ekshyyan O, Aw TY. Apoptosis in acute and chronic neurological disorders. Front Biosci. 2004;91567–1576.
   PubMed Web of Science ®Google Scholar
• Elliott R. Executive functions and their disorders: imaging in clinical neuroscience. Br Med Bull. 2003;65(1):49–59.
   PubMed Web of Science ®Google Scholar
• Ezquerra M, Campdelacreu J, Gaig C, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease. Neurosci Lett. 2008. 448(1):20–23.
   PubMed Web of Science ®Google Scholar
• Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA Arch Neurol. 1999;56(5):529–535.
   PubMed Web of Science ®Google Scholar
• Fall PA, Axelson O, Fredriksson M, et al. Age-standardized incidence and prevalence of Parkinson’s disease in a Swedish community. J Clin Epidemiol. 1996;49(6):637–641.
   PubMed Web of Science ®Google Scholar
• Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14(6):625–639.
   PubMed Web of Science ®Google Scholar
• Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson’s disease: rationale and current status. CNS Drugs. 2010;24(3):177–192.
   PubMed Web of Science ®Google Scholar
• Ferraye M, Debu B, Fraix V, et al. Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson disease. Neurology. 2008;70(16):1431–1437.
   PubMed Web of Science ®Google Scholar
• Ferris HU, Dunin-Horkawicz S, Mondéjar LG, et al. The mechanisms of HAMP-mediated signaling in transmembrane receptors. Structure. 2011;19(3):378–385.
   PubMed Web of Science ®Google Scholar
• Ferro MM, Bellissimo MI, Anselmo-Franci JA, et al. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson’s disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods. 2005;148(1):78–87.
   PubMed Web of Science ®Google Scholar
• Fornai F, Schlüter OM, Lenzi P, et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA. 2005;102(9):3413–3418.
   PubMed Web of Science ®Google Scholar
• Forssberg H, Johnels B, Steg G. Is Parkinsonian gait caused by a regression to an immature walking pattern? Adv Neurol. 1984;40:375–379.
   PubMedGoogle Scholar
• Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. 2001;344(10):710–719.
   PubMed Web of Science ®Google Scholar
• Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72.
   PubMed Web of Science ®Google Scholar
• Freitas ME, Ruiz-Lopez M, Fox SH. Novel Levodopa formulations for Parkinson’s disease. CNS Drugs. 2016;30:1079–1095.
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Vigouroux S, Wong H, et al. Brain proteasomal function in sporadic Parkinson’s disease and related disorders. Ann Neurol. 2002;51(6):779–782.
   PubMed Web of Science ®Google Scholar
• Fuxe K, Agnati L, Jacobsen K, et al. Receptor heteromerization in adenosine A2A receptor signaling Relevance for striatal function and Parkinson’s disease. Neurology. 2003;61(11):S19–S23.
   PubMedGoogle Scholar
• Gainetdinov RR, Bohn LM, Sotnikova TD, et al. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron. 2003;38(2):291–303.
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25(15):2493–2500.
   PubMed Web of Science ®Google Scholar
• Gantchev N, Viallet F, Aurenty R, et al. Impairment of posturo-kinetic co-ordination during initiation of forward oriented stepping movements in parkinsonian patients. Electroencephalogr Clin Neurophysiol. 1996;101(2):110–120.
   PubMedGoogle Scholar
• Gao HM, Jiang J, Wilson B, et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem. 2002;81(6):1285–1297.
   PubMed Web of Science ®Google Scholar
• Garbayo E, Montero-Menei C, Ansorena E, et al. Effective GDNF brain delivery using microspheres-a promising strategy for Parkinson’s disease. J Control Release. 2009;135(2):119–126.
   PubMed Web of Science ®Google Scholar
• García-Arencibia M, García C, Fernández-Ruiz J. Cannabinoids and Parkinson’s disease. CNS Neurol Disord Drug Targets. 2009;8(6):432–439.
   PubMed Web of Science ®Google Scholar
• García-Arencibia M, González S, de Lago E, et al. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007;1134:162–170.
   PubMed Web of Science ®Google Scholar
• Gasser T. Genetics of Parkinson’s disease. Curr Opin Neurol. 2005;18(4):363–369.
   PubMed Web of Science ®Google Scholar
• Geed M, Garabadu D, Ahmad A, et al. Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP + injection in rats. Pharmacol Biochem Behav. 2014;117:92–103.
   PubMed Web of Science ®Google Scholar
• Gélat T, Coudrat L, Le Pellec A. Gait initiation is affected during emotional conflict. Neurosci Lett. 2011;497(1):64–67.
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–39.
   PubMed Web of Science ®Google Scholar
• Gerdeman GL, Partridge JG, Lupica CR, et al. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci. 2003;26(4):184–192.
   PubMed Web of Science ®Google Scholar
• Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol. 2014;112:24–49.
   PubMed Web of Science ®Google Scholar
• Gibb W, Lees A. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1991;54(5):388–396.
   PubMed Web of Science ®Google Scholar
• Giladi N, Shabtai H, Rozenberg E, et al. Gait festination in Parkinson’s disease. Parkinsonism Relat Disord. 2001;7(2):135–138.
   PubMed Web of Science ®Google Scholar
• Giladi N, Shabtai H, Simon E, et al. Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord. 2000;6(3):165–170.
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 2001;40(8):959–975.
   PubMed Web of Science ®Google Scholar
• Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet. 2005;365(9457):415–416.
   PubMed Web of Science ®Google Scholar
• Giráldez-Pérez RM, Antolín-Vallespín M, Muñoz MD, et al. Models of α-synuclein aggregation in Parkinson’s disease. Acta Neuropathol Commun. 2014;2(1):176.
   PubMed Web of Science ®Google Scholar
• Gjerstad M, Wentzel-Larsen T, Aarsland D, et al. Insomnia in Parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry. 2007;78(5):476–479.
   PubMed Web of Science ®Google Scholar
• González S, Scorticati C, García-Arencibia M, et al. Effects of rimonabant, a selective cannabinoid CB 1 receptor antagonist, in a rat model of Parkinson’s disease. Brain Res. 2006;1073:209–219.
   PubMed Web of Science ®Google Scholar
• Goodwin VA, Richards SH, Taylor RS, et al. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2008;23(5):631–640.
   PubMed Web of Science ®Google Scholar
• Gorell JM, Johnson C, Rybicki B, et al. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50(5):1346–1350.
   PubMed Web of Science ®Google Scholar
• Granieri E, Carreras M, Casetta I, et al. Parkinson’s disease in Ferrara, Italy, 1967 through 1987. Arch Neurology. 1991;48(8):854–857.
   PubMedGoogle Scholar
• Gray JA, McNaughton N. The neuropsychology of anxiety: an enquiry into the function of the septo-hippocampal system. Oxford: Oxford University Press; 2003.
   Google Scholar
• Grealish S, Diguet E, Kirkeby A, et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson’s disease. Cell Stem Cell. 2014;15(5):653–665.
   PubMed Web of Science ®Google Scholar
• Greenamyre JT, MacKenzie G, Peng TI, et al. Mitochondrial dysfunction in Parkinson’s disease. Biochem Soc Symp; 1999:66:85–97.
   Google Scholar
• Gupta A, Pulliam L. Exosomes as mediators of neuroinflammation. J Neuroinflammation. 2014;11(1):68.
   PubMed Web of Science ®Google Scholar
• Haehner A, Hummel T, Reichmann H. Olfactory dysfunction as a diagnostic marker for Parkinson’s disease. Exp Rev Neurother. 2009;9(12):1773–1779.
   PubMed Web of Science ®Google Scholar
• Hanakawa T, Katsumi Y, Fukuyama H, et al. Mechanisms underlying gait disturbance in Parkinson’s disease: a single photon emission computed tomography study. Brain. 1999;122(7):1271–1282.
   Google Scholar
• Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release. 2015; 207:18–30.
   PubMed Web of Science ®Google Scholar
• Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol. 1983;40(3):151–154.
   PubMedGoogle Scholar
• Hass CJ, Waddell DE, Fleming RP, et al. Gait initiation and dynamic balance control in Parkinson’s disease. Arch Phys Med Rehabil. 2005;86(11):2172–2176.
   PubMed Web of Science ®Google Scholar
• Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Nat Acad Sci. 1996;93(5):1956–1961.
   PubMed Web of Science ®Google Scholar
• Hauber W. Blockade of subthalamic dopamine D1 receptors elicits akinesia in rats. Neuroreport. 1998;9(18):4115–4118.
   PubMed Web of Science ®Google Scholar
• Hausdorff JM, Balash Y, Giladi N. Time series analysis of leg movements during freezing of gait in Parkinson’s disease: akinesia, rhyme or reason? Physica A. 2003;321(3):565–570.
   Web of Science ®Google Scholar
• Hawkes C, Shephard B, Daniel S. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62(5):436–446.
   PubMed Web of Science ®Google Scholar
• Hawlitschka A, Haas SJ, Schmitt O, et al. Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats. Brain Res. 2007;1173:137–144.
   PubMed Web of Science ®Google Scholar
• Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Ann Rev Physiol. 2009;71:283–306.
   PubMed Web of Science ®Google Scholar
• Hellenbrand W, Boeing H, Robra BP, et al. Diet and Parkinson’s disease II A possible role for the past intake of specific nutrients: results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996;47(3):644–650.
   PubMed Web of Science ®Google Scholar
• Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600–609.
   PubMedGoogle Scholar
• Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–397.
   PubMed Web of Science ®Google Scholar
• Hoffman AF, Oz M, Caulder T, Lupica CR. Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci. 2003;23(12):4815–4820.
   PubMed Web of Science ®Google Scholar
• Hohler AD, Zuzuárregui JRP, Katz DI, et al. Differences in motor and cognitive function in patients with Parkinson’s disease with and without orthostatic hypotension. Int J Neurosci. 2012;122(5):233–236.
   Web of Science ®Google Scholar
• Holloway R, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–1053.
   PubMedGoogle Scholar
• Holroyd S, Currie LJ, Wooten GF. Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology. 2005;64(12):2134–2135.
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966;18(2):925–964.
   PubMed Web of Science ®Google Scholar
• Howe TE, Lövgreen B, Cody FW, et al. Auditory cues can modify the gait of persons with early-stage Parkinson’s disease: a method for enhancing parkinsonian walking performance? Clin Rehabil. 2003;17(4):363–367.
   PubMed Web of Science ®Google Scholar
• Howitt J, Hill AF. Exosomes in the pathology of neurodegenerative diseases. J Biol Chem. 2016;291(52):26589–26597.
   PubMed Web of Science ®Google Scholar
• Hsu HY, Wen MH. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem. 2002;277(25):22131–22139.
   PubMed Web of Science ®Google Scholar
• Hsu SD, Tseng YT, Shrestha S, et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2014;42(D1):D78–D85.
   PubMed Web of Science ®Google Scholar
• Huang W, Chen Y, Shohami E, et al. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366(2–3):127–135.
   PubMed Web of Science ®Google Scholar
• Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204–1222.
   PubMed Web of Science ®Google Scholar
• Huber SJ, Shuttleworth EC, Paulson GW. Dementia in Parkinson’s disease. Arch Neurol. 1986;43(10):987–990.
   PubMedGoogle Scholar
• Hunn BH, Cragg SJ, Bolam JP, et al. Impaired intracellular trafficking defines early Parkinson’s disease. Trends Neurosci. 2015;38(3):178–188.
   PubMed Web of Science ®Google Scholar
• Hussian G, Manyam BV. Mucuna pruriens proves more effective than L-DOPA in Parkinson’s disease animal model. Phytother Res. 1997;11(6):419–423.
   Web of Science ®Google Scholar
• Ii K, Ito H, Tanaka K, et al. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol. 1997;56(2):125–131.
   PubMed Web of Science ®Google Scholar
• Iravani MM, Kashefi K, Mander P, et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience. 2002;110(1):49–58.
   PubMed Web of Science ®Google Scholar
• Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson’s disease dementia: convergence of [alpha]-synuclein, tau and amyloid-[beta] pathologies. Nat Rev Neurosci. 2013;14(9):626–636.
   PubMed Web of Science ®Google Scholar
• Jackson-Lewis V, Vila M, Tieu K, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002;22(5):1763–1771.
   PubMed Web of Science ®Google Scholar
• Jacobs JV, Nutt JG, Carlson-Kuhta P, et al. Knee trembling during freezing of gait represents multiple anticipatory postural adjustments. Exp Neurol. 2009;215(2):334–341.
   PubMed Web of Science ®Google Scholar
• Jakowec MW, Nixon K, Hogg E, et al. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J Neurosci Res. 2004;6(4):539–550.
   Web of Science ®Google Scholar
• Jankovic J. Pathophysiology and clinical assessment of motor symptoms in Parkinson’s disease. Handbook Parkinsons Dis. 1987;2:129–157.
   Google Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008; 79(4):368–376.
   PubMed Web of Science ®Google Scholar
• Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40(10):1529.
   PubMed Web of Science ®Google Scholar
• Janvin CC, Larsen JP, Salmon DP, et al. Cognitive profiles of individual patients with Parkinson’s disease and dementia: comparison with dementia with lewy bodies and Alzheimer’s disease. Mov Disord. 1990;21(3):337–342.
   Web of Science ®Google Scholar
• Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology. 1996;47(6):161S–170S.
   Web of Science ®Google Scholar
• Jollivet C, Aubert-Pouessel A, Clavreul A, et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson’s disease. Biomaterials. 2004;25(5):933–942.
   PubMed Web of Science ®Google Scholar
• Julian M, Martin A, Cuellar B, et al. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience. 2003;119(1):309–318.
   PubMed Web of Science ®Google Scholar
• Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs. 2000;59(6):1233–1250.
   PubMed Web of Science ®Google Scholar
• Kalani A, Tyagi A, Tyagi N. Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol. 2014;49(1):590–600.
   PubMed Web of Science ®Google Scholar
• Kang J, Park EJ, Jou I, et al. Reactive oxygen species mediate A beta(25–35)-induced activation of BV-2 microglia. Neuroreport. 2001;12(7):1449–1452.
   PubMed Web of Science ®Google Scholar
• Kastner A, Hirsch E, Lejeune O, et al. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson’s disease related to their neuromelanin content? J Neurochem. 1992;59(3):1080–1089.
   PubMed Web of Science ®Google Scholar
• Katiyar SK. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). Int J Oncol. 2005;26(1):169–176.
   PubMed Web of Science ®Google Scholar
• Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11(2):79–92.
   PubMed Web of Science ®Google Scholar
• Kempster PA, O’Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133(6):1755–1762.
   PubMed Web of Science ®Google Scholar
• Keränen T, Gordin A, Harjola V, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol. 1993;16(2):145–156.
   PubMed Web of Science ®Google Scholar
• Kerr G, Worringham CJ, Cole MH, et al. Predictors of future falls in Parkinson disease. Neurology. 2010;75(2):116–124.
   PubMed Web of Science ®Google Scholar
• Kim HA, Mindos T, Parkinson DB. Plastic fantastic: Schwann cells and repair of the peripheral nervous system. Stem Cells Trans Med. 2013a;2(8):553–557.
   PubMed Web of Science ®Google Scholar
• Kim M, Cho KH, Shin MS, et al. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson’s disease. Int J Mol Med. 2014;33(4):870–878.
   PubMed Web of Science ®Google Scholar
• Kim SD, Allen NE, Canning CG, et al. Postural instability in patients with Parkinson’s disease. Epidemiology, pathophysiology and management. CNS Drugs. 2013b;27(2):97–112.
   PubMed Web of Science ®Google Scholar
• Kim WG, Mohney RP, Wilson B, et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci. 2000;20(16):6309–6316.
   PubMed Web of Science ®Google Scholar
• Kirsch-Darrow L, Marsiske M, Okun MS, et al. Apathy and depression: separate factors in Parkinson’s disease. J Int Neuropsychol Soc. 2011;17(6):1058–1066.
   PubMed Web of Science ®Google Scholar
• Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318(14):876–880.
   PubMed Web of Science ®Google Scholar
• Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(1):a008888.
   PubMed Web of Science ®Google Scholar
• Knight JA. Reactive oxygen species and the neurodegenerative disorders. Ann Clin Lab Sci. 1997;27(1):11–25.
   PubMed Web of Science ®Google Scholar
• Kong LY, McMillian MK, Hudson PM, et al. Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. J Pharmacol Exp Ther. 1997;280(1):61–66.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. New Eng J Med. 1995;332(17):1118–1124.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys. Ann Neurol. 2006;60(2):264–268.
   PubMed Web of Science ®Google Scholar
• Korell M, Tanner CM. Epidemiology of Parkinson’s disease: an overview. Parkinson’s disease. Boca Raton (FL): CRC Press; 2005. p. 39–50.
   Google Scholar
• Kowall NW, Hantraye P, Brouillet E, et al. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 2000;11(1):211–213.
   PubMed Web of Science ®Google Scholar
• Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature. 2007;445(7128):643–647.
   PubMed Web of Science ®Google Scholar
• Kriks S, Shim J-W, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature. 2011;480(7378):547–551.
   PubMed Web of Science ®Google Scholar
• Krystkowiak P, Delval A, Dujardin K, et al. Gait abnormalities induced by acquired bilateral pallidal lesions: a motion analysis study. J Neurol. 2006;253(5):594–600.
   PubMed Web of Science ®Google Scholar
• Kukula-Koch W, Kruk-Słomka M, Stępnik K, The evaluation of pro-cognitive and antiamnestic properties of berberine and magnoflorine isolated from Barberry species by centrifugal partition chromatography (CPC), in relation to QSAR modelling. Int J Mol Sci. 2017;18(12):2511.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res. 2010;24(3):317–324.
   PubMed Web of Science ®Google Scholar
• Kuopio AM, Marttila RJ, Helenius H, et al. Changing epidemiology of Parkinson’s disease in southwestern Finland. Neurology. 1999;52(2):302.
   PubMed Web of Science ®Google Scholar
• Kusumi M, Nakashima K, Harada H, et al. Epidemiology of Parkinson’s disease in Yonago City, Japan: comparison with a study carried out 12 years ago. Neuroepidemiology. 1996;15(4):201–207.
   PubMed Web of Science ®Google Scholar
• Kwak Y, Peltier S, Bohnen NI, et al. Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson’s disease. Front Syst Neurosci. 2010; 4:143.
   Google Scholar
• Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19(R1):R46–R64.
   PubMed Web of Science ®Google Scholar
• Lange KW, Robbins T, Marsden C, et al. L-dopa withdrawal in Parkinson’s disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology. 1992;107(2–3):394–404.
   PubMed Web of Science ®Google Scholar
• Lauterbach EC, Freeman A, Vogel RL. Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2004;16(1):29–36.
   PubMed Web of Science ®Google Scholar
• Lee Y, Park HR, Chun HJ, et al. Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease via mitochondrial stabilization. J Neurosci Res. 2015;93(5):755–765.
   PubMed Web of Science ®Google Scholar
• Lennox G, Lowe J, Morrell K, et al. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry. 1989;52(1):67–71.
   PubMed Web of Science ®Google Scholar
• Lesage S, Condroyer C, Lannuzel A, et al. Molecular analyses of the LRRK2 gene in European and North-African autosomal dominant Parkinson’s disease. J Med Genet. 2009;46:458–464.
   PubMed Web of Science ®Google Scholar
• Lev N, Melamed E, Offen D. Apoptosis and Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(2):245–250.
   PubMed Web of Science ®Google Scholar
• Lewitt P. Micrographia as a focal sign of neurological disease. J Neurol Neurosurg Psychiatry. 1983;46(12):1152.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295–302.
   PubMed Web of Science ®Google Scholar
• Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501–503.
   PubMed Web of Science ®Google Scholar
• Li SC, Schoenberg BS, Wang CC, et al. A prevalence survey of Parkinson’s disease and other movement disorders in the People’s Republic of China. Arch Neurol. 1985;42(7):655–657.
   PubMedGoogle Scholar
• Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999;5(12):1403–1409.
   PubMed Web of Science ®Google Scholar
• Libman I, Gawel MJ, Riopelle RJ, et al. A comparison of bromocriptine (Parlodel®) and levodopa-carbidopa (Sinemet®) for treatment of “de novo” Parkinson’s disease patients. Can J Neurol Sci. 1987;14(4):576–580.
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–795.
   PubMed Web of Science ®Google Scholar
• Linazasoro G, Nanotechnologies for Neurodegenerative Diseases Study Group of the Basque Country (NANEDIS). Potential applications of nanotechnologies to Parkinson’s disease therapy. Parkinsonism Relat Disord. 2008;14(5):383–392.
   PubMed Web of Science ®Google Scholar
• Linder J, Stenlund H, Forsgren L. Incidence of Parkinson’s disease and parkinsonism in northern Sweden: a population-based study. Mov Disord. 2010;25(3):341–348.
   PubMed Web of Science ®Google Scholar
• Lindvall O, Björklund A. Cell therapy in Parkinson’s disease. NeuroRx. 2004;1(4):382–393.
   PubMedGoogle Scholar
• Ling Z, Zhu Y, wai Tong C, et al. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol. 2006;199(2):499–512.
   PubMed Web of Science ®Google Scholar
• Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung. 1992;80(1–4):363–367.
   PubMed Web of Science ®Google Scholar
• Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27(3):349–356.
   PubMed Web of Science ®Google Scholar
• Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther. 2000a;293(2):607–617.
   PubMed Web of Science ®Google Scholar
• Liu B, Jiang JW, Wilson BC, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther. 2000b;295(1):125–132.
   PubMed Web of Science ®Google Scholar
• Liu YM, Niu L, Wang LL, et al. Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice. Brain Res Bull. 2017;134:220–227.
   PubMed Web of Science ®Google Scholar
• Lotharius J, O'Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation A novel mechanism of toxicity. J Biol Chem. 2000;275(49):38581–38588.
   PubMed Web of Science ®Google Scholar
• Low PA. Prevalence of orthostatic hypotension. Clin Auton Res. 2008;18(1):8–13.
   PubMed Web of Science ®Google Scholar
• Lowe J, McDermott H, Landon M, et al. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol. 1990;161(2):153–160.
   PubMed Web of Science ®Google Scholar
• Lu FM, Yuan Z. PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg. 2015;5(3):433.
   PubMed Web of Science ®Google Scholar
• Lu L, Liu D, Ceng X, Ma L. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci. 2000;12(12):4398–4404.
   PubMed Web of Science ®Google Scholar
• Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949–953.
   PubMed Web of Science ®Google Scholar
• Luo Z, Ahlers KE, Yang J, et al. Regulator of G-protein signaling 6 (RGS6) expression in human substantia nigra pars compacta (SNc) and loss in Parkinson’s disease (PD). FASEB J. 2017;31(1):659.
   Google Scholar
• Lyons KE, Pahwa R. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (Stalevo) in Parkinson disease patients. Clin Neuropharmacol. 2006;29(2):73–76.
   PubMed Web of Science ®Google Scholar
• MacDonald B, Cockerell O, Sander J, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123(4):665–676.
   PubMed Web of Science ®Google Scholar
• Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res. 2005;15(2):76–82.
   PubMed Web of Science ®Google Scholar
• Manning-Boğ AB, Reaney SH, Chou VP, et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol. 2006;60(2):256–260.
   PubMed Web of Science ®Google Scholar
• Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18(9):706–712.
   PubMed Web of Science ®Google Scholar
• Marneweck M, Hammond G. Voluntary control of facial musculature in Parkinson’s disease. J Neurol Sci. 2014;347(1–2):332–336.
   PubMed Web of Science ®Google Scholar
• Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord. 2013;28(5):626–633.
   PubMed Web of Science ®Google Scholar
• Marras C, McDermott MP, Rochon PA, et al. Predictors of deterioration in health-related quality of life in Parkinson’s disease: results from the DATATOP trial. Mov Disord. 2008;23(5):653–659.
   PubMed Web of Science ®Google Scholar
• Marsden C, Parkes J. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet. 1977;1(8007):345–349.
   PubMed Web of Science ®Google Scholar
• Marsh L, McDonald W, Cummings J, et al. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord. 2006;21(2):148–158.
   PubMed Web of Science ®Google Scholar
• Marsh L, Vaughan C, Schretlen D, et al. 542. Psychomotor aspects of mood disorders in Parkinson’s disease. Biol Psychiatry. 2000;47(8):S165.
   Web of Science ®Google Scholar
• Martinez-Martin P, Pecurariu CF, Odin P, et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. J Neurol. 2012;259(8):1639–1647.
   PubMed Web of Science ®Google Scholar
• Massano J, Garrett C. Deep brain stimulation and cognitive decline in Parkinson’s disease: a clinical review. Front Neurol. 2012;3:66.
   PubMedGoogle Scholar
• Massi P, Vaccani A, Parolaro D. Cannabinoids, immune system and cytokine network. Curr Pharm Des. 2006;12(24):3135–3146.
   PubMed Web of Science ®Google Scholar
• Massman PJ, Delis DC, Butters N, et al. Are all subcortical dementias alike? Verbal learning and memory in Parkinson’s and Huntington’s disease patients. J Clin Exp Neuropsychol. 1990;12(5):729–744.
   PubMed Web of Science ®Google Scholar
• Matinolli M, Korpelainen JT, Korpelainen R, et al. Orthostatic hypotension, balance and falls in Parkinson’s disease. Mov Disord. 2009;24(5):745–751.
   PubMed Web of Science ®Google Scholar
• Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol. 1995;142(8):820–827.
   PubMed Web of Science ®Google Scholar
• McGeer P, Itagaki S, Boyes B, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8):1285.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–1124.
   PubMed Web of Science ®Google Scholar
• McLennan J, Nakano K, Tyler H, et al. Micrographia in Parkinson’s disease. J Neurol Sci. 1972;15(2):141–152.
   PubMed Web of Science ®Google Scholar
• McNaught KSP, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett. 2001;297(3):191–194.
   PubMed Web of Science ®Google Scholar
• McNaught KSP, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s disease. Ann Neurol. 2003;53(3):S73–84.
   PubMed Web of Science ®Google Scholar
• McNaught KSP, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol Aging. 2006;27(4):530–545.
   PubMed Web of Science ®Google Scholar
• McNaught KSP, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol. 2004;56(1):149–162.
   PubMed Web of Science ®Google Scholar
• Meireles J, Massano J. Cognitive impairment and dementia in Parkinson’s disease: clinical features, diagnosis, and management. Front Neurol. 2012;3:88.
   PubMedGoogle Scholar
• Melcon MO, Anderson DW, Vergara RH, et al. Prevalence of Parkinson’s disease in Junin, Buenos Aires Province, Argentina. Move Disord. 1997;12(2):197–205.
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886–892.
   PubMed Web of Science ®Google Scholar
• Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson’s disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993;34(7):465–470.
   PubMed Web of Science ®Google Scholar
• Migliore L, Coppedè F. Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat Res. 2009;674(1):73–84.
   PubMed Web of Science ®Google Scholar
• Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann NY Acad Sci. 2010;1184(1):154–172.
   PubMed Web of Science ®Google Scholar
• Modi PK, Komaravelli N, Singh N, et al. Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neurons. Mol Biol Cell. 2012;23(18):3722–3730.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Kondo T, et al. Brain β2-microglobulin levels are elevated in the striatum in Parkinson’s diseaselevels are elevated in the striatum in Parkinson’s disease. J Neural Transm Parkinsons Dis Dement Sect. 1995;9(1):87–92.
   PubMedGoogle Scholar
• Mogi M, Togari A, Kondo T, et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson’s disease. Neurosci Lett. 1999;270(1):45–48.
   PubMed Web of Science ®Google Scholar
• Moore ST, MacDougall HG, Ondo WG. Ambulatory monitoring of freezing of gait in Parkinson’s disease. J Neurosci Methods. 2008;167(2):340–348.
   PubMed Web of Science ®Google Scholar
• More SV, Choi DK. Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection. Mol Neurodegener. 2015;10(1):17.
   PubMed Web of Science ®Google Scholar
• Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11(7):589–596.
   PubMed Web of Science ®Google Scholar
• Moreau C, Ozsancak C, Blatt JL, et al. Oral festination in Parkinson’s disease: biomechanical analysis and correlation with festination and freezing of gait. Mov Disord. 2007;22(10):1503–1506.
   PubMed Web of Science ®Google Scholar
• Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB 1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Prac Res Clin Endocrinol Metab. 2009;23(1):133–144.
   PubMed Web of Science ®Google Scholar
• Morens D, Grandinetti A, Waslien C, et al. Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology. 1996;46(5):1270.
   PubMed Web of Science ®Google Scholar
• Munhoz R, Li JY, Kurtinecz M, et al. Evaluation of the pull test technique in assessing postural instability in Parkinson’s disease. Neurology. 2004;62(1):125–127.
   PubMed Web of Science ®Google Scholar
• Muslimović D, Post B, Speelman JD, et al. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239–1245.
   PubMed Web of Science ®Google Scholar
• Nackaerts E, Nieuwboer A, Broeder S, et al. Altered effective connectivity contributes to micrographia in patients with Parkinson’s disease and freezing of gait. J Neurol. 2017;265:336–347.
   PubMed Web of Science ®Google Scholar
• Nagatsu T. Parkinson’s disease: changes in apoptosis-related factors suggesting possible gene therapy. J Neural Transm. 2002;109(5):731–745.
   PubMed Web of Science ®Google Scholar
• Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol. 1984;15(5):415–418.
   PubMed Web of Science ®Google Scholar
• Nakata Y, Yasuda T, Mochizuki H. Recent progress in gene therapy for Parkinson’s disease. Curr Mol Med. 2012;12(10):1311–1318.
   PubMed Web of Science ®Google Scholar
• Nerurkar AC, Sheth M. Facial, Oromotor and Speech disturbances in individuals with Parkinson’s disease. Int J Ther Rehabil Res. 2017;6(2):217.
   Google Scholar
• Nieuwboer A, Dom R, De Weerdt W, et al. Abnormalities of the spatiotemporal characteristics of gait at the onset of freezing in Parkinson’s disease. Mov Disord. 2001;16(6):1066–1075.
   PubMed Web of Science ®Google Scholar
• Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci. 2000;23:S8–S19.
   PubMed Web of Science ®Google Scholar
• Oka H, Yoshioka M, Onouchi K, et al. Retracted: characteristics of orthostatic hypotension in Parkinson’s disease. Brain. 2007;130(9):2425–2432.
   PubMed Web of Science ®Google Scholar
• Olanow C, Tatton W. Etiology and pathogenesis of Parkinson’s disease. Ann Rev Neurosci. 1999;22:123–144.
   PubMed Web of Science ®Google Scholar
• Oliveira RM, Gurd JM, Nixon P, et al. Micrographia in Parkinson’s disease: the effect of providing external cues. J Neurol Neurosurg Psychiatry. 1997;63(4):429–433.
   PubMed Web of Science ®Google Scholar
• Ongini E, Monopoli A, Impagnatiello F, et al. Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes. Drug Dev Res. 2001;52(1):379–386.
   Web of Science ®Google Scholar
• Ouachikh O, Chassain C, Pagès G, et al. mGlu5 receptor antagonist blocks bromocriptine-induced conditioned place preference in bilateral mesolimbic-lesioned rat. Behav Brain Res. 2017;317:301–310.
   PubMed Web of Science ®Google Scholar
• Owen A, James M, Leigh P, et al. Fronto-striatal cognitive deficits at different stages of Parkinson’s disease. Brain. 1992;115(6):1727–1751.
   PubMed Web of Science ®Google Scholar
• Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66(8):1200–1206.
   PubMed Web of Science ®Google Scholar
• Pan T, Kondo S, Le W, et al. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain. 2008;131(8):1969–1978.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Mash DC. Insular pathology in Parkinson’s disease patients with orthostatic hypotension. Parkinsonism Relat Disord. 2007;13(5):308–311.
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Alves G, Larsen JP, et al. Psychometric properties of the Starkstein Apathy Scale in patients with early untreated Parkinson disease. Am J Geriatr Psychiatry. 2012;20(2):142–148.
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Larsen JP, Alves G, et al. Prevalence and clinical correlates of apathy in Parkinson’s disease: a community-based study. Parkinsonism Relat Disord. 2009;15(4):295–299.
   PubMed Web of Science ®Google Scholar
• Peralta C, Stampfer-Kountchev M, Karner E, et al. Orthostatic hypotension and attention in Parkinson’s disease with and without dementia. J Neural Transm (Vienna). 2007;114(5):585–588.
   PubMed Web of Science ®Google Scholar
• Pérez HJ, Carrillo SC, García E, et al. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson’s disease. Toxicology. 2014;319:38–43.
   PubMed Web of Science ®Google Scholar
• Perier C, Tieu K, Guégan C, et al. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA. 2005;102(52):19126–19131.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2003;2(2):107–116.
   PubMed Web of Science ®Google Scholar
• Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol. 2007;83(1):84–92.
   PubMed Web of Science ®Google Scholar
• Poewe W, Högl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson’s disease. Neurology. 2004;63(8):S12–S16.
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Molloy S, et al. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010;25(11):1646–1651.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–2047.
   PubMed Web of Science ®Google Scholar
• Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Mov Disord. 2009;24(9):1333–1338.
   PubMed Web of Science ®Google Scholar
• Pontone GM, Williams JR, Anderson KE, et al. Anxiety and self-perceived health status in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(4):249–254.
   PubMed Web of Science ®Google Scholar
• Qin L, Liu Y, Cooper C, Liu B, et al. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem. 2002;83(4):973–983.
   PubMed Web of Science ®Google Scholar
• Qiu A, Fennema-Notestine C, Dale AM, et al. Regional shape abnormalities in mild cognitive impairment and Alzheimer’s disease. Neuroimage. 2009;45(3):656–661.
   PubMed Web of Science ®Google Scholar
• Quinn N. Drug treatment of Parkinson’s disease. Br Med J. 1995;310(6979):575.
   PubMed Web of Science ®Google Scholar
• Rajendran L, Honsho M, Zahn TR, et al. Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA. 2006;103(30):11172–11177.
   PubMed Web of Science ®Google Scholar
• Rangasamy SB, Soderstrom K, Bakay RA, et al. Neurotrophic factor therapy for Parkinson’s disease. Prog Brain Res. 2010;184:237–264.
   PubMed Web of Science ®Google Scholar
• Rasola A, Bernardi P. Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium. 2011;50(3):222–233.
   PubMed Web of Science ®Google Scholar
• Reeve J. Understanding motivation and emotion. Hoboken (NJ): John Wiley & Sons; 2014.
   Google Scholar
• Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183–189.
   PubMed Web of Science ®Google Scholar
• Ricaurte G, Irwin I, Forno L, et al. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 1987;403(1):43–51.
   PubMed Web of Science ®Google Scholar
• Rideout HJ, Lang-Rollin IC, Savalle M, et al. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up‐regulate iHSP70, following proteasomal inhibition. J Neurochem. 2005;93(5):1304–1313.
   PubMed Web of Science ®Google Scholar
• Robertson D. The pathophysiology and diagnosis of orthostatic hypotension. Clin Auton Res. 2008;18(1):2–7.
   PubMed Web of Science ®Google Scholar
• Rogers J, Mastroeni D, Leonard B, et al. Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int Rev Neurobiol. 2007;82:235–246.
   PubMed Web of Science ®Google Scholar
• Rosati G, Granieri E, Pinna L, et al. The risk of Parkinson disease in Mediterranean people. Neurology. 1980;30(3):250.
   PubMed Web of Science ®Google Scholar
• Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 2006;114(7):630–636.
   PubMed Web of Science ®Google Scholar
• Salarian A, Russmann H, Wider C, et al. Quantification of tremor and bradykinesia in Parkinson’s disease using a novel ambulatory monitoring system. IEEE Trans Biomed Eng. 2007;54(2):313–322.
   PubMed Web of Science ®Google Scholar
• Salat D, Tolosa E. Levodopa in the treatment of Parkinson’s disease: current status and new developments. J Parkinsons Dis. 2013;3(3):255–269.
   PubMedGoogle Scholar
• Sanlioglu S, Williams CM, Samavati L, et al. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem. 2001;276(32):30188–30198.
   PubMed Web of Science ®Google Scholar
• Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257–1263.
   PubMed Web of Science ®Google Scholar
• Sapir S, Ramig L, Fox C. Speech and swallowing disorders in Parkinson disease. Curr Opin Otolaryngol Head Neck Surg. 2008;16(3):205–210.
   PubMed Web of Science ®Google Scholar
• Savica R, Grossardt BR, Bower JH, et al. Time trends in the incidence of Parkinson disease. JAMA Neurol. 2016;73(8):981–989.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord. 2011;26(6):1049–1055.
   PubMed Web of Science ®Google Scholar
• Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002;160(5):1655–1667.
   PubMed Web of Science ®Google Scholar
• Schon EA, Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest. 2003;111(3):303.
   PubMed Web of Science ®Google Scholar
• Schrag A. Quality of life and depression in Parkinson’s disease. J Neurol Sci. 2006;248(1–2):151–157.
   PubMed Web of Science ®Google Scholar
• Schulz J, Dehmer T, Schöls L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology. 2000;55(11):1719–1721.
   PubMed Web of Science ®Google Scholar
• Scott S, Caird F, Williams B. Evidence for an apparent sensory speech disorder in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1984;47(8):840–843.
   PubMed Web of Science ®Google Scholar
• Seljeseth YM, Vollset SE, Tysnes OB. Increasing mortality from amyotrophic lateral sclerosis in Norway? Neurology. 2000;55(9):1262–1266.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol. 2004;6(11):1054–1061.
   PubMed Web of Science ®Google Scholar
• Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42(7):1328.
   PubMed Web of Science ®Google Scholar
• Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol. 2010;48(3):803–806.
   PubMed Web of Science ®Google Scholar
• Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J Neurosci. 2002;22(16):7006–7015.
   PubMed Web of Science ®Google Scholar
• Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 2001;29(1):15–32.
   PubMed Web of Science ®Google Scholar
• Shi M, Liu C, Cook TJ, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol. 2014;128(5):639–650.
   PubMed Web of Science ®Google Scholar
• Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, et al. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene: a predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson’s disease. Biochem Biophys Res Commun. 1996;226(2):561–565.
   PubMed Web of Science ®Google Scholar
• Shin JY, Hendrix CC. Management of patients with Parkinson disease. Nurse Pract. 2013;38(10):34–43.
   PubMedGoogle Scholar
• Siddiqui M, Rast S, Lynn M, et al. Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey. Parkinsonism Relat Disord. 2002;8(4):277–284.
   PubMed Web of Science ®Google Scholar
• Simpkins CO, Ives N, Tate E, et al. Naloxone inhibits superoxide release from human neutrophils. Life Sci. 1985;37(15):1381–1386.
   PubMed Web of Science ®Google Scholar
• Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson’s disease. Eur Neurol. 1992;32(3):134–140.
   PubMed Web of Science ®Google Scholar
• Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson’s disease. Prog Neurobiol. 2007;81(1):29–44.
   PubMed Web of Science ®Google Scholar
• Singh RP, Sharad S, Kapur S. Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants. J Indian Acad Clin Med. 2004;5(3):218–225.
   Google Scholar
• Singleton A, Farrer M, Johnson J, et al. α-alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302(5646):841.
   PubMed Web of Science ®Google Scholar
• Smith KS, Smith PL, Heady TN, et al. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol. 2003;16(2):123–128.
   PubMed Web of Science ®Google Scholar
• Solla P, Cannas A, Marrosu F, et al. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat. 2010;6:483.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VMY, et al. α- Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–840.
   PubMed Web of Science ®Google Scholar
• Stam C, Visser S, Op de Coul A, et al. Disturbed frontal regulation of attention in Parkinson’s disease. Brain. 1993;116(5):1139–1158.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Merello M, Jorge R, et al. The syndromal validity and nosological position of apathy in Parkinson's disease. Mov Disord. 2009;24(8):1211–1216.
   PubMed Web of Science ®Google Scholar
• Stichel CC, Schoenebeck B, Foguet M, et al. sgk1, a member of an RNA cluster associated with cell death in a model of Parkinson’s disease. Eur J Neurosci. 2005;21(2):301–316.
   PubMed Web of Science ®Google Scholar
• Stuendl A, Kunadt M, Kruse N, et al. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies. Brain. 2015;139(2):481–494.
   PubMed Web of Science ®Google Scholar
• Suchowersky O, Gronseth G, Perlmutter J, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):976–982.
   PubMed Web of Science ®Google Scholar
• Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trend Neurosci. 2007;30(5):244–250.
   PubMed Web of Science ®Google Scholar
• Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18(2):101–113.
   PubMed Web of Science ®Google Scholar
• Sutcliffe R, Meara J. Parkinson’s disease epidemiology in the Northampton district, England, 1992. Acta Neurol Scand. 1995;92(6):443–450.
   PubMed Web of Science ®Google Scholar
• Swainson R, Rogers R, Sahakian B, et al. Probabilistic learning and reversal deficits in patients with Parkinson’s disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia. 2000;38(5):596–612.
   PubMed Web of Science ®Google Scholar
• Tanner CM, Langston JW, Klawans H, et al. Do environmental toxins cause Parkinson’s disease? A critical review. Neurology. 1990;40(10):17–31.
   Web of Science ®Google Scholar
• Tatton WG, Chalmers-Redman R, Brown D, et al. Apoptosis in Parkinson’s disease: signals for neuronal degradation. Ann Neurol. 2003;53(S3) S61–70.
   PubMed Web of Science ®Google Scholar
• Taylor C, Saint-Hilaire M, Cupples L, et al. Environmental, medical, and family history risk factors for Parkinson’s disease: a New England‐based case control study. Am J Med Genetics. 1999;88(6):742–749.
   PubMed Web of Science ®Google Scholar
• Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003;112(6):892.
   PubMed Web of Science ®Google Scholar
• Tofaris GK, Razzaq A, Ghetti B, et al. Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. 2003;278(45):44405–44411.
   PubMed Web of Science ®Google Scholar
• Tomlinson PR, Zheng Y, Fischer R, et al. Identification of distinct circulating exosomes in Parkinson’s disease. Ann Clin Transl Neurol. 2015;2(4):353–361.
   PubMed Web of Science ®Google Scholar
• Ueki A, Otsuka M. Life style risks of Parkinson’s disease: association between decreased water intake and constipation. J Neurol. 2004;251(7):vii18–vii23.
   PubMedGoogle Scholar
• Vaillancourt D, Spraker M, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009;72(16):1378–1384.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.
   PubMed Web of Science ®Google Scholar
• Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 1997;349(9062):1391–1392.
   PubMed Web of Science ®Google Scholar
• Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–1022.
   PubMed Web of Science ®Google Scholar
• Van Emmerik RE, Wagenaar RC, Winogrodzka A, et al. Identification of axial rigidity during locomotion in Parkinson disease. Arch Phys Med Rehabil. 1999;80(2):186–191.
   PubMed Web of Science ®Google Scholar
• Vásquez-Vivar J, Kalyanaraman B, Kennedy MC. Mitochondrial aconitase is a source of hydroxyl radical an electron spin resonance investigation. J Biol Chem. 2000;275(19):14064–14069.
   PubMed Web of Science ®Google Scholar
• Vasto S, Candore G, Balistreri CR, et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev. 2007;128(1):83–91.
   PubMed Web of Science ®Google Scholar
• Vella LJ, Hill AF, Cheng L. Focus on extracellular vesicles: exosomes and their role in protein trafficking and biomarker potential in Alzheimer’s and Parkinson’s Disease. Int J Mol Sci. 2016;17(2):173.
   PubMed Web of Science ®Google Scholar
• Vercruysse S, Gilat M, Shine JM, et al. Freezing beyond gait in Parkinson’s disease: a review of current neurobehavioral evidence. Neurosci Biobehav Rev. 2014;43:213–227.
   PubMed Web of Science ®Google Scholar
• Verwoert GC, MattaceRaso FU, Hofman A, et al. Orthostatic hypotension and risk of cardiovascular disease in elderly people: the Rotterdam study. J Am Geriatr Soc. 2008;56(10):1816–1820.
   PubMed Web of Science ®Google Scholar
• Vigouret J, Bürki H, Jaton A, et al. Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25–397 and CM 29–712. Pharmacology. 1978;16(1):156–173.
   PubMed Web of Science ®Google Scholar
• Vijverman AC, Fox SH. New treatments for the motor symptoms of Parkinson’s disease. Exp Rev Clin Pharm. 2014;7(6):761–777.
   PubMed Web of Science ®Google Scholar
• Vilming S. Diet therapy in Parkinson disease. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. Tidsskr Nor Laegeforen. 1995;115(10):1244–1247.
   PubMedGoogle Scholar
• Vlasov PN, Kamelkova E, Drozzhina F. Efficacy and tolerance of intravenous lacosamide in urgent neurological situations. Neurol Neuropsychiatry Psychosomat. 2012;30(1S):60–63.
   Google Scholar
• von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473–490.
   PubMed Web of Science ®Google Scholar
• Wahner AD, Bronstein JM, Bordelon YM, et al. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology. 2007;69(19):1836–1842.
   PubMed Web of Science ®Google Scholar
• Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359–407.
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci. 2016;17(4):251–260.
   PubMed Web of Science ®Google Scholar
• Walsh K, Bennett G. Parkinson’s disease and anxiety. Postgrad Med J. 2001;77(904):89–93.
   PubMed Web of Science ®Google Scholar
• Wang JJ. Group reminiscence therapy for cognitive and affective function of demented elderly in Taiwan. Int J Geriatr Psychiatry. 2007;22(12):1235–1240.
   PubMed Web of Science ®Google Scholar
• Wang Y, Butros SR, Shuai X, et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2012;33(2):266–273.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi Y, Wu Z, et al. Parkinson’s disease in China. Coordinational group of neuroepidemiology, PLA. Chin Med J. 1991;104(11):960–964.
   PubMed Web of Science ®Google Scholar
• Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson’s disease. Neurology. 1983;33(7):943.
   PubMed Web of Science ®Google Scholar
• Waters C, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Neurology. 1997;49(3):665–671.
   PubMed Web of Science ®Google Scholar
• Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Burn DJ. Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord. 2011;26(6):1022–1031.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Comella CL, Horn S. Parkinson’s disease-part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008;14(2):S40–S48.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969–973.
   PubMedGoogle Scholar
• Weiss ML, Medicetty S, Bledsoe AR, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson’s disease. Stem Cell. 2006;24(3):781–792.
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, Chen H, Schwarzschild MA, et al. Prospective study of phobic anxiety and risk of Parkinson’s disease. Mov Disord. 2003;18(6):646–651.
   PubMed Web of Science ®Google Scholar
• Wersinger C, Sidhu A. An inflammatory pathomechanism for Parkinson’s disease? Curr Med Chem. 2006;13(5):591–602.
   PubMed Web of Science ®Google Scholar
• Williams-Gray C, Foltynie T, Brayne C, et al. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007;130(Pt 7):1787–1798.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(Pt 11):2958–2969.
   PubMed Web of Science ®Google Scholar
• Winslow AR, Chen CW, Corrochano S, et al. α-Synuclein impairs macroautophagy: implications for Parkinson’s disease. J Cell Biol. 2010;190(6):1023–1037.
   PubMed Web of Science ®Google Scholar
• Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson’s disease. Mov Disord. 2005;20(9):1104–1108.
   PubMed Web of Science ®Google Scholar
• Wooten G, Currie L, Bovbjerg V, et al. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry. 2004;75(4):637–639.
   PubMed Web of Science ®Google Scholar
• Wu T, Chan P, Hallett M. Effective connectivity of neural networks in automatic movements in Parkinson’s disease. Neuroimage. 2010;49(3):2581–2587.
   PubMed Web of Science ®Google Scholar
• Wu T, Hallett M. A functional MRI study of automatic movements in patients with Parkinson’s disease. Brain. 2005;128(Pt 10):2250–2259.
   PubMed Web of Science ®Google Scholar
• Yadav SK, Prakash J, Chouhan S, et al. Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model. Neurochem Int. 2014;65:1–13.
   PubMed Web of Science ®Google Scholar
• Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord. 2011;26(14):2496–2503.
   PubMed Web of Science ®Google Scholar
• Yarnall AJ, Rochester L, Baker MR, et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson’s disease? Mov Disord. 2013;28(9):1285–1288.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555.
   PubMed Web of Science ®Google Scholar
• York G. The history of James Parkinson and his disease. J Neurol Sci. 2017;381:35.
   Web of Science ®Google Scholar
• Yuan L, Deng X, Song Z, et al. Genetic analysis of the RAB39B gene in Chinese Han patients with Parkinson’s disease. Neurobiol Aging. 2015;36(10):2907– e2912.
   Web of Science ®Google Scholar
• Zecca L, Tampellini D, Gerlach M, et al. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. MP Mol Pathol. 2001;54(6):414.
   PubMedGoogle Scholar
• Zeng BY, Iravani MM, Lin ST, et al. MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome. Eur J Neurosci. 2006;23(7):1766–1774.
   PubMed Web of Science ®Google Scholar
• Zeng XS, Jia JJ, Kwon Y, et al. The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease. Free Radic Biol Med. 2014;67:10–18.
   PubMed Web of Science ®Google Scholar
• Zou K, Li Z, Zhang Y, et al. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sinica. 2017;38(2):157–167.
   PubMed Web of Science ®Google Scholar